IIT Guwahati has released the GATE 2026 Syllabus for Computer Science & Information Technology (CS&IT) along with the ...

Breastfeeding following breast cancer did not increase risk for recurrence or contralateral disease for women who participated in the POSITIVE trial.In a cohort of more than 300 women with early ...

Breast cancer care is no longer about aggressive, one-size-fits-all approaches, but a quiet revolution toward smarter, less ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Dick Fiske, who died on June 18 as he neared his 93rd birthday, was one of the most original thinkers ever at the USGS ...

Candel Therapeutics offers strong risk-reward potential with robust multi-cancer drug data, solid finances, and FDA Fast ...

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year ...

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. This is a joint post with Michael Weilandt, Research Associate at the Council on ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Cancer's most insidious ability lies not just in its capacity to grow, but in its power to transform. When tumor cells ...